Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II feasibility study of EP-2104R for MRI imaging of arterial and cardiac thrombi
2004-004701-23Phase 2Completed
- Sponsor
- Epix Pharmaceuticals
- Start
- Feb 2005
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EP-2104R in arterial thrombosis and intracardiac thrombosis, sponsored by Epix Pharmaceuticals. Primary endpoint: Signal intensity of thrombus over time. Started Feb 2005; status: completed.
02
Drugs
EP-2104R
03
Conditions
arterial thrombosisintracardiac thrombosis
Beyond the preview
Go deeper on 2004-004701-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004701-23.